The GHRH agonist peptide MR-409 prevented retinal damage in diabetic rats by reducing inflammation, oxidative stress, and vascular leakage, while preserving retinal ganglion cell survival.
Retinal Ganglion Cells PreservedGHRH agonist MR-409 prevented retinal nerve cell death in diabetic rats while simultaneously reducing inflammation, oxidative stress, and vascular leakage
What the researchers found
In streptozotocin-induced diabetic rats, treatment with the GHRH agonist MR-409 (15 μg/kg) prevented retinal morphological damage and particularly preserved retinal ganglion cell survival. MR-409 upregulated NRF-2-dependent antioxidant gene expression, downregulated pro-inflammatory cytokines and adhesion molecules, reduced VEGF expression while increasing PEDF expression, and decreased vascular permeability. GHRH and GHRH-R expression were significantly downregulated in both diabetic rat retinas and human diabetic retinas (postmortem). Treatment with the GHRH antagonist MIA-602 worsened retinal morphology, confirming that GHRH signaling is neuroprotective.
Why it matters
Current treatments for diabetic retinopathy (laser therapy, anti-VEGF injections) address late-stage disease. GHRH agonists could offer a new approach targeting early disease by simultaneously protecting neurons, reducing inflammation, fighting oxidative stress, and preventing vascular damage — addressing multiple pathological mechanisms with a single peptide-based therapy.
How the study worked
Researchers used streptozotocin-induced diabetic rats treated with the GHRH agonist MR-409 (15 μg/kg) or antagonist MIA-602. Retinal morphology was assessed histologically. Gene and protein expression were measured using qPCR and Western blotting for GHRH-R, inflammatory markers, oxidative stress pathways (NRF-2), and angiogenic factors (VEGF, PEDF). Vascular permeability was quantified. Human diabetic retinas (postmortem) were also analyzed for GHRH-R expression.
What this study cannot tell us
This is a preclinical study in diabetic rats, and results may not directly translate to human diabetic retinopathy. The streptozotocin model mimics type 1 diabetes, while most diabetic retinopathy occurs in type 2 diabetes. The study examined early-stage retinopathy and did not assess whether MR-409 can reverse established disease. Long-term safety data for retinal use of GHRH agonists is lacking.
How to read the evidence
This is an original preclinical study published in PNAS with both animal and human tissue data. The mechanistic evidence is thorough, with multiple complementary approaches (morphology, gene expression, protein analysis, vascular permeability). The human postmortem retina data strengthens translational relevance.
When this study was published
Published in 2017 in PNAS, this study established GHRH agonists as potential retinal neuroprotectants. Further development may have progressed since publication.
The bigger picture
GHRH is primarily known for stimulating growth hormone release, but this study reveals a direct tissue-protective role in the retina independent of growth hormone. This adds to growing evidence that GHRH analogs have therapeutic potential beyond endocrinology — in conditions involving inflammation, oxidative stress, and neurovascular injury. The finding that GHRH-R is downregulated in human diabetic retinas validates the translational relevance of this work.
Questions still open
- Would GHRH agonists be effective in human diabetic retinopathy, and could they be delivered directly to the eye?
- Can MR-409 reverse established retinal damage or is it only protective when given early?
- Does the GHRH-R downregulation seen in diabetic retinas occur early enough to serve as a biomarker for disease onset?
Common questions
What is GHRH and how could it help diabetic eye disease?
Is this different from current diabetic retinopathy treatments?
Read the original research
Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy.
Proceedings of the National Academy of Sciences of the United States of America, 114(50), 13248-13253
Citation
Thounaojam, Menaka C; Powell, Folami L; Patel, Sagar; Gutsaeva, Diana R; Tawfik, Amany; Smith, Sylvia B; Nussbaum, Julian; Block, Norman L; Martin, Pamela M; Schally, Andrew V; Bartoli, Manuela. (2017). Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy.. Proceedings of the National Academy of Sciences of the United States of America, 114(50), 13248-13253. https://doi.org/10.1073/pnas.1718592114